Email updates

Keep up to date with the latest news and content from Breast Cancer Research and BioMed Central.

Highly Accessed Viewpoint

Estrogen-related receptor alpha: an orphan finds a family

Aleksandra M Ochnik and Douglas Yee*

Author Affiliations

Masonic Cancer Center, Departments of Medicine and Pharmacology, University of Minnesota, MMC 806, 420 Delaware Street SE, Minneapolis, MN 55455, USA

For all author emails, please log on.

Breast Cancer Research 2012, 14:309  doi:10.1186/bcr3124

The electronic version of this article is the complete one and can be found online at: http://breast-cancer-research.com/content/14/3/309


Published:10 May 2012

© 2012 BioMed Central Ltd

Abstract

Identification of molecules and their effectors has led to new therapies designed to specifically inhibit pathways in molecularly defined breast cancer subtypes. An orphan nuclear receptor, estrogen-related receptor alpha, has been shown to be a downstream target of two tyrosine kinase growth factor receptors: human epidermal growth factor receptor 2 and the type I insulin-like growth factor receptor. Identifying the mechanistic actions of orphan nuclear receptors could lead to new biomarkers and molecular targets in malignancy.

Background

Nuclear receptors (NRs) are well accepted as critical mediators in many aspects of breast cancer pathogenesis. Molecular cloning of estrogen receptor alpha (ERα) has demonstrated how molecular targeting of specific domains of a single protein can improve outcomes. Molecular cloning techniques have revealed receptors related to ERα, including the 'estrogen-related receptor' (ERR) family.

Recent prognostic studies have demonstrated that overexpression of one of these family members, ERRα, is associated with a poor outcome in patients with ER- breast cancer [1], yet the transcriptional regulation of the orphan receptor ERRα is still not well known. Overexpression of ERRα has been shown to be associated with elevated human epidermal growth factor 2 (HER2) expression [2], and ERRα can interact with the co-regulators PGC-1 α and β (peroxisome proliferator-activated gamma co-activator-1 alpha and beta) [3,4] in addition to a number of p160 co-activators [5,6]. Interestingly, ERRα displays distinct subtype transcriptional activation that is not similarly identified by ER [7]. Unlike ERα, which has been targeted by ligand deprivation (oophorectomy and aromatase inhibitors) and selective estrogen receptor modulators (tamoxifen and fulvestrant), ERRα has no known ligand and therefore is not amenable to drug inhibition in the same fashion.

If ERRα regulates breast cancer cells, then we need to understand its mechanism of action. Since there are no known ways to target ERRα+ ER- breast cancers, molecular techniques could be used (a) to gain an understanding of how ERRα modulates gene expression in breast cancer subtypes [8-11] and (b) to develop potential therapeutic approaches to target ERRα-driven tumors [12].

The article

Chang and colleagues [12] created normal human mammary epithelial cell lines overexpressing ERRα to better understand its transcriptional targets. Since no ligand exists for ERRα, overexpression of the well-characterized co-regulator of ERRα, PGC-1α, was used to activate transcription [3]. Unsupervised gene clustering analysis and binary regression modeling defined transcriptomes associated with 'low or high ERRα activity'. When applied to seven clinical breast cancer microarray gene sets, high ERRα activity was shown to be associated with poorer prognosis. Experiments using an ERRα antagonist in normal human mammary epithelial cells that ranged in low, medium, and high ERRα expression showed a positive correlation between an intrinsic ERRα gene expression signature and breast cancer growth.

The authors further identified a relationship between increased ERRα activity via the upregulation of the ERRα co-activator PGC-1β. Inhibitors of the type I insulin-like growth factor receptor (IGF-1R) and HER2 receptors or PI3K/AKT pathway blocked this upregulation whereas mitogen-activated protein kinase inhibitors did not. Lastly, it was identified that heregulin and IGF-1 treatment led to increased C-MYC protein expression or recruitment to intron 1 of the PGC-1β gene (or both) to stimulate expression. The authors of another recent paper [13] have identified a similar dual relationship between androgen-dependent, androgen receptor (AR) signaling promotion of tumor growth in the molecular apocrine subtype of breast cancer (that is, ER-/AR+) by the up-stream actions of WNT and HER2/HER3 signaling pathways [14]. Collectively, these findings identify a new role for the 'orphan' ERRα as a transcriptional regulator of PI3K and growth factor signaling via C-MYC activation of the PGC-1β promoter and invite new cellular strategies to be tested in specific molecular subtypes of breast cancer.

The viewpoint

Breast cancer treatment would be simpler if a single protein regulated a single pathway in all cancer cells. This is never the case, and the orchestrated interplay of tyrosine kinase growth factor signaling pathways and NR activity reveals complex interconnected pathways relevant to tumor biology. Moreover, it is now evident that, in order to accurately assess and target NR activity in breast cancer, both the upstream and downstream modulators associated with aspects of NR gene regulation need to be appreciated. This group has previously shown a role for ERRα in cancer cell motility [15], and it would be important to know whether the gene signatures for ERRα stimulated motility and proliferation are the same.

Chang and colleagues [12] have furthered the idea that 'orphans' are regulated in a coordinated manner to affect breast cancer biology. Upstream activation of cell signaling is necessary to fully reveal the biology mediated by ERRα. Given this complex system, it is evident that measurement of ERRα alone will reveal very little about its activation state; deeper investigation into signaling molecules, adaptor proteins, and gene signatures will be required to fully assess its biological significance. Understanding these molecular interactions is necessary to answer important clinical questions. How do we use our current understanding of the interplay of growth factor and NR signaling to design the most effective clinical treatments for breast cancer? Is it better to target the downstream targets or the upstream drivers of cancer-promoting growth factor intracellular signaling pathways or both? How do we find the key nodes regulated by these molecular signaling systems to exploit as therapies?

There are clearly multiple upstream drivers of a single downstream mediator and vice versa. Thus, future clinical trials must be carefully designed to identify the key convergence sites and to employ appropriate therapies designed to adequately impinge on their downstream effectors. Chang and colleagues have shown that just because you're an orphan doesn't mean that you're not important! By revealing functions for ERRα, these authors have suggested how future therapeutic treatment strategies need to reflect and complement the continually evolving molecular complexity of breast cancer.

Abbreviations

AR: androgen receptor; ER: estrogen receptor; ERR: estrogen-related receptor; IGF-1: type I insulin-like growth factor; NR: nuclear receptor; PGC: peroxisome proliferator-activated gamma co-activator-1.

Competing interests

The authors declare that they have no competing interests.

References

  1. Ariazi EA, Kraus RJ, Farrell ML, Jordan VC, Mertz JE: Estrogen-related receptor alpha1 transcriptional activities are regulated in part via the ErbB2/HER2 signaling pathway.

    Mol Cancer Res 2007, 5:71-85. PubMed Abstract | Publisher Full Text OpenURL

  2. Ariazi EA, Clark GM, Mertz JE: Estrogen-related receptor alpha and estrogen-related receptor gamma associate with unfavorable and favorable biomarkers, respectively, in human breast cancer.

    Cancer Res 2002, 62:6510-6518. PubMed Abstract | Publisher Full Text OpenURL

  3. Kallen J, Schlaeppi JM, Bitsch F, Filipuzzi I, Schilb A, Riou V, Graham A, Strauss A, Geiser M, Fournier B: Evidence for ligand-independent transcriptional activation of the human estrogen-related receptor alpha (ERRalpha): crystal structure of ERRalpha ligand binding domain in complex with peroxisome proliferator-activated receptor coactivator-1alpha.

    J Biol Chem 2004, 279:49330-49337. PubMed Abstract | Publisher Full Text OpenURL

  4. Kamei Y, Ohizumi H, Fujitani Y, Nemoto T, Tanaka T, Takahashi N, Kawada T, Miyoshi M, Ezaki O, Kakizuka A: PPARgamma coactivator 1beta/ERR ligand 1 is an ERR protein ligand, whose expression induces a high-energy expenditure and antagonizes obesity.

    Proc Natl Acad Sci USA 2003, 100:12378-12383. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  5. Xie W, Hong H, Yang NN, Lin RJ, Simon CM, Stallcup MR, Evans RM: Constitutive activation of transcription and binding of coactivator by estrogen-related receptors 1 and 2.

    Mol Endocrinol 1999, 13:2151-2162. PubMed Abstract | Publisher Full Text OpenURL

  6. Zhang Z, Teng CT: Estrogen receptor-related receptor alpha 1 interacts with coactivator and constitutively activates the estrogen response elements of the human lactoferrin gene.

    J Biol Chem 2000, 275:20837-20846. PubMed Abstract | Publisher Full Text OpenURL

  7. Deblois G, Hall JA, Perry MC, Laganière J, Ghahremani M, Park M, Hallett M, Giguère V: Genome-wide identification of direct target genes implicates estrogen-related receptor alpha as a determinant of breast cancer heterogeneity.

    Cancer Res 2009, 69:6149-6157. PubMed Abstract | Publisher Full Text OpenURL

  8. Perou CM: Molecular stratification of triple-negative breast cancers.

    Oncologist 2010, 15(Suppl 5):39-48. PubMed Abstract | Publisher Full Text OpenURL

  9. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D: Molecular portraits of human breast tumours.

    Nature 2000, 406:747-752. PubMed Abstract | Publisher Full Text OpenURL

  10. Prat A, Perou CM: Deconstructing the molecular portraits of breast cancer.

    Mol Oncol 2011, 5:5-23. PubMed Abstract | Publisher Full Text OpenURL

  11. Rody A, Karn T, Liedtke C, Pusztai L, Ruckhaeberle E, Hanker L, Gaetje R, Solbach C, Ahr A, Metzler D, Schmidt M, Müller V, Holtrich U, Kaufmann M: A clinically relevant gene signature in triple negative and basal-like breast cancer.

    Breast Cancer Res 2011, 13:R97. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  12. Chang CY, Kazmin D, Jasper JS, Kunder R, Zuercher WJ, McDonnell DP: The metabolic regulator ERRalpha, a downstream target of HER2/IGF-1R, as a therapeutic target in breast cancer.

    Cancer Cell 2011, 20:500-510. PubMed Abstract | Publisher Full Text OpenURL

  13. Ni M, Chen Y, Lim E, Wimberly H, Bailey ST, Imai Y, Rimm DL, Liu XS, Brown M: Targeting androgen receptor in estrogen receptor-negative breast cancer.

    Cancer Cell 2011, 20:119-131. PubMed Abstract | Publisher Full Text OpenURL

  14. Farmer P, Bonnefoi H, Becette V, Tubiana-Hulin M, Fumoleau P, Larsimont D, Macgrogan G, Bergh J, Cameron D, Goldstein D, Duss S, Nicoulaz AL, Brisken C, Fiche M, Delorenzi M, Iggo R: Identification of molecular apocrine breast tumours by microarray analysis.

    Oncogene 2005, 24:4660-4671. PubMed Abstract | Publisher Full Text OpenURL

  15. Dwyer MA, Joseph JD, Wade HE, Eaton ML, Kunder RS, Kazmin D, Chang CY, McDonnell DP: WNT11 expression is induced by estrogen-related receptor alpha and beta-catenin and acts in an autocrine manner to increase cancer cell migration.

    Cancer Res 2010, 70:9298-9308. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL